23 completed, 8 unknown, 6 terminated, 2 recruiting. 40 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 40 | Completed 23, Unknown 8, Terminated 6, Recruiting 2, Withdrawn 1 |
| Phase 2 | 3 | Unknown 2, Recruiting 1 |
Follow Donepezil: new trials by email Literature Review of Donepezil trials Research Report on Donepezil
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Study to Evaluate the Efficacy and Safety of Huperzine A Controlled-Release Tablets in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type Huperzine A Controlled-Release Tablets, Donepezil hydrochloride tablets, Huperzine A controlled-release tablets placebo; Donepezil hydrochloride tablets placebo - Alzheimer Dementia | Phase 2 / Phase 3 | Recruiting | Wanbangde Pharmaceutical Group Co., LTD | 720 | 2025-08-29 | 2026-08-17 |
| Donepezil Versus Non-drug Treatment in Alzheimer's Disease. Donepezil - Alzheimer Disease, Early Onset | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 240 | 2022-02-10 | 2026-02-18 |
| A Phase 2 Clinical Study to Explore the Optimal Dosage/Administration of PM012 Tablet in Alzheimer's Disease PM012, PM012 Placebo, Donepezil - Mild Alzheimer Disease | Phase 2 / Phase 3 | Unknown | Mediforum Ltd., Co. | 312 | 2020-11-27 | 2023-04-18 |
| Brain Correlates of Multimodal Rehabilitation in Chronic Post-stroke Aphasia Donepezil, Intensive-Language Action Therapy, Transcranial direct current stimulation - Aphasia, Stroke | Phase 3 | Completed | University of Malaga | 20 | 2019-01-08 | 2020-11-05 |
| Donepezil Attenuate Postoperative Cognitive Dysfunction Donepezil, Placebo - Osteoarthritis, Femoral Head Necrosis | Phase 3 | Unknown | RenJi Hospital | 550 | 2018-09-01 | 2020-01-30 |
| A Multinational, Multi-center, Randomized, Double-blind, Active Comparator, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Donepezil Transdermal Patch in Patients With Alzheimer's Disease Donepezil patch, aricept Tab - Alzheimer Disease | Phase 3 | Completed | Icure Pharmaceutical Inc. | 399 | 2017-10-12 | 2021-02-11 |
| Octohydroaminoacridine Succinate Tablet for Mild-to-Moderate Alzheimer's Disease Octohydroaminoacridine Succinate, Aricept, Placebos - Alzheimer Disease | Phase 3 | Unknown | Shanghai Mental Health Center | 600 | 2017-08-16 | 2019-10-22 |
| Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil Donepezil 5 mg, Placebo - Cognitive Dysfunction, Memory Impairment | Phase 3 | Completed | Wake Forest University Health Sciences | 276 | 2017-05-30 | 2023-09-13 |
| Clinical Efficacy of Ginkgo Biloba Extract in the Treatment of Alzheimer's Disease Ginkgo biloba dispersible tablets, Donepezil, Ginkgo biloba dispersible tablets and Donepezil - Alzheimer's | Phase 2 / Phase 3 | Unknown | The First Affiliated Hospital with Nanjing Medical University | 240 | 2016-08-10 | 2019-08-07 |
| Pharmacovigilance in Gerontopsychiatric Patients Phenobarbital, Phenytoin, Carbamazepine - Dementia, Depression | Phase 3 | Terminated | Hannover Medical School | 407 | 2015-01-01 | 2018-02-28 |
| Optimal Dose Escalation Strategy to Successful Achievement of High Dose Donepezil 23mg donepezil - Alzheimer's Disease | Phase 3 | Completed | Asan Medical Center | 176 | 2014-12-01 | 2018-08-07 |
| Efficacy and Safety of Tianzhi Granule in Mild to Moderate Vascular Dementia Tianzhi granule and placebo identified to donepezil, Donepezil and placebo identified to Tianzhi granule, Placebo - Vascular Dementia | Phase 3 | Completed | Dongzhimen Hospital, Beijing | 543 | 2013-10-01 | 2020-01-07 |
| Zydena on Cognitive Function of Alzheimer's Disease Patients Zydena (Udenafil) 50mg + Donepezil 5mg or 10mg, Placebo + Donepezil 5mg or 10mg, Zydena (Udenafil) 100mg + Donepezil 5mg or 10mg - Alzheimer's Disease | Phase 3 | Unknown | Samsung Medical Center | 210 | 2013-09-01 | 2013-09-12 |
| Multicenter Evaluation of Memory Remediation After TBI With Donepezil Donepezil, Placebo - Traumatic Brain Injury, Memory Deficits | Phase 3 | Completed | Baylor College of Medicine | 75 | 2013-09-01 | 2025-01-15 |
| Multi-centre UK Study of the Acetylcholinesterase Inhibitor Donepezil in Early Dementia Associated With Parkinson's Disease Donepezil - Parkinson's Disease | Phase 3 | Terminated | Newcastle-upon-Tyne Hospitals NHS Trust | 64 | 2013-01-01 | 2017-09-25 |
| Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease E2020 - Alzheimer's Type Dementia | Phase 3 | Completed | Eisai Co., Ltd. | 351 | 2012-03-01 | 2023-06-18 |
| A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease E2020, Placebo - Alzheimer's Type Dementia | Phase 3 | Completed | Eisai Limited | 260 | 2011-09-01 | 2017-03-08 |
| A Study of E2020 in Patients With Dementia With Lewy Bodies (DLB), Followed by a Long-term Extension Phase Donepezil 5 mg, Donepezil 10 mg, Donepezil matched placebo - Dementia With Lewy Bodies (DLB) | Phase 3 | Completed | Eisai Co., Ltd. | 142 | 2011-02-01 | 2023-06-29 |
| Discontinuation of Cholinesterase Inhibitors for the Treatment of Severe Alzheimer's Disease Cholinesterase Inhibitor, Placebo - Alzheimer's Disease, Dementia | Phase 3 | Completed | Sunnybrook Health Sciences Centre | 40 | 2010-07-01 | 2017-04-28 |
| Enhancing Rehabilitation After Stroke donepezil, placebo - Ischemic Stroke | Phase 3 | Unknown | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 200 | 2009-03-01 | 2013-03-05 |
Showing 20 of 40. Sign in to see all of them.
Alzheimer Disease (16) · Cognitive Dysfunction (9) · Dementia (8) · Brain Diseases (3) · Central Nervous System Diseases (3) · Delirium (3) · Dementia, Vascular (3) · Memory Disorders (3) · Nervous System Diseases (3) · Stroke (3) · Depression (2) · Down Syndrome (2) · Mental Disorders (2) · Neurodegenerative Diseases (2) · Pain (2)
Eisai Inc. (7) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (3) · Eisai Co., Ltd. (2) · Eisai Limited (2) · Pfizer (2) · Wake Forest University Health Sciences (2) · Alliance for Clinical Trials in Oncology (1) · Asan Medical Center (1) · Assistance Publique - Hôpitaux de Paris (1) · Baylor College of Medicine (1) · Beersheva Mental Health Center (1) · Dongzhimen Hospital, Beijing (1) · Hannover Medical School (1) · Icure Pharmaceutical Inc. (1) · M.D. Anderson Cancer Center (1)
United States (16) · China (7) · Canada (6) · South Korea (5) · France (3) · Germany (3) · United Kingdom (3) · Australia (2) · Ireland (2) · Japan (2) · Spain (2) · Argentina (1) · Chile (1) · Israel (1) · Netherlands (1)
Jane Yardley, Ph.D (2) · Jinzhou Tian, MD,PhD (2) · Naoki Kubota (2) · Thomas McRae, MD (2) · Alistair Burns, Professor (1) · Aminah Jatoi, MD (1) · Andrew J Lees, Professor (1) · Angelle Sander, PhD (1) · Belinda Braithwaite, Mrs (1) · Carl E Clarke, Professor (1) · Daniel Weintraub (1) · David Arciniegas, MD (1) · David J Burn, Professor (1) · Diansan Su, M.D., Ph.D. (1)
PMID 14732621, PMID 15480814, PMID 17210817, PMID 20678673, PMID 21612646, PMID 21689411, PMID 22572767, PMID 22930699, PMID 24073978, PMID 25713599, PMID 25713600, PMID 26482056, PMID 28596794, PMID 31039806, PMID 32054507, PMID 34518459, PMID 35433325, PMID 35719690, PMID 36627206, PMID 36641605, PMID 36879199, PMID 38709986
3UG1CA189824-04S1 (1), P01HD024448 (1), U01AG010483 (1), U10CA081851 (1)